摘要
目的探讨伊立替康和顺铂联合沙利度胺治疗复发性小细胞肺癌的疗效与不良反应。方法选取同时期的62例复发性小细胞肺癌患者，按不平衡指数最小的分配原则随机分为观察组和对照组，观察组采用伊立替康和顺铂联合沙利度胺化疗；对照组采用常规伊立替康和顺铂化疗。比较两组患者疗效及不良反应。结果观察组和对照组的客观有效率分别为86．7％和63．3％；两组临床疗效比较差异有统计学意义（χ2=8．52，P〈0．05）；主要不良反应为血液学毒性和消化道症状，观察组和对照组比较差异无统计学意义（χ2=0．18，P〉0．05）。结论伊立替康和顺铂联合沙利度胺治疗复发晚期小细胞肺癌，有效率高，不良反应可以耐受。
Objective To investigate the efficacy and toxicity of thalidomide plus irinotecan and cispl- atin treatment for recurrent small cell lung cancer. Methods 62 Patients with recurrent small cell lung cancer in the same period were randomly divided into observation group and control group according to the principle of minimum distribution imbalance index. The observation group patients were treated with thalidomide plus irino- teean and cisplatin chemotherapy, and the control group patients were treated with irinotecan and cisplatin chemotherapy. The efficacy and toxicity of the two groups were compared. Results The overall response rate in the group observation was 86.7% compared with 63.3% in the control group, and the difference had statisti- cal significance （ χ2 = 8. 52, P 〈 0.05 ）. The major toxicities were hematologic toxicity and gastrointestinal symptoms, and the side effects differences were not statistically significant （χ2 = 0.18 ,P 〉 0.05 ）. Conclusion The treatment of recurrent small cell lung cancer with irinotecan and cisplatin in combination with thalidomide has high efficiency, and the toxicity can be tolerated.
出处
《国际肿瘤学杂志》
CAS
2013年第4期306-308,共3页
Journal of International Oncology
关键词
肺肿瘤
肿瘤复发
药物疗法
联合
Lung neoplasms
Neoplasm recurrence
Drug therapy, combination
